Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Rationale The availability of the highly selective and specific kappa opioid agonist enadoline provides an opportunity to explore the function of kappa receptors in humans and their potential utility as a target for substance abuse pharmacotherapy development.Objectives The purpose of this study was to characterize the pharmacodynamic effects of enadoline, a selective kappa agonist, and to compare it with butorphanol, a mixed mu/kappa agonist, and hydromorphone, a mu agonist, in humans.Methods Pilot evaluation (n=3) served to establish intramuscular doses of enadoline (20, 40, 80, and 160 microg/70 kg), butorphanol (1.5, 3, 6, and 12 mg/70 kg), and hydromorphone (1.5, 3, and 6 mg/70 kg) of comparable activity. These acute doses were examined under double-blind, placebo-controlled and constrained randomized conditions with a minimum of 72 h between tests in volunteers with polysubstance abuse histories (n=6). Physiological and subject- and observer-rated measures were collected 30 min before and for 4 h after administration.Results Enadoline significantly increased measures of sedation, confusion and dizziness, produced visual distortions and feelings of depersonalization, and increased urinary output. The highest dose (160 microg/70 kg) was not tolerated and led to psychotomimetic effects. Hydromorphone produced prototypic mu opioid effects including respiratory depression, miosis, and euphoria. Butorphanol was most similar to hydromorphone and shared few effects with enadoline.Conclusions These results are discussed with respect to the potential use and safety of kappa agonists for clinical indications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A kappa-opioid receptor agonist, enadoline, increased feelings of depersonalization in a small sample of individuals with histories of substance abuse [112].”
From Treatment of dissociative identity disorder: leveraging neurobiology to optimize success (2024) · cites this paper as [112]
Citations
Cites
Opioid analgesics and antagonists
Reisine, T. (1996) · Medical Entomology and Zoology · Cited by 1,205
Martin, W. R., Sloan, J. W., Sapira, J. D., & Jasinski, D. R. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part1245 · Cited by 943
Psychotomimesis Mediated by κ Opiate Receptors
Pfeiffer, A., Brantl, V., Herz, A., & Emrich, H. M. (1986) · Science · doi:10.1126/science.3016896 · Cited by 857 · cited 3×
“These adverse effects have led some researchers to classify kappa agonists as psychotomimetics ( Pfeiffer et al. 1986 ) and have contributed to the failure of some of these agents in clinical trials.”
BackgroundResultInfluentialInteractions between Kappa Opioid Agonists and Cocaine: Preclinical Studies
Mello, N. K., & Negus, S. S. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06678.x · Cited by 247
The reinforcing and subjective effects of morphine in post-addicts: a dose-response study.
Lamb, R. J., Preston, K. L., Schindler, C. W., Meisch, R. A., Davis, F., Katz, J. L., Henningfield, J. E., & Goldberg, S. R. (1991) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20504-3 · Cited by 245 · cited 1×
“whereby morphine is perceived as dysphoric in drug-naive individuals but euphorigenic in experienced users ( Lamb et al. 1991; Zacny et al. 1994a).”
BackgroundFraser, H. F., Van Horn, G. D., Martin, W. R., Wolbach, A. B., & Isbell, H. (1961) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)26118-3 · Cited by 232
Assessment of the Abuse Potentiality of Morphinelike Drugs (Methods Used in Man)
Jasinski, D. R. (1977) · Drug Addiction I · doi:10.1007/978-3-642-66612-4_4 · Cited by 200
Hill, J. L., & Zacny, J. P. (2000) · Psychopharmacology · doi:10.1007/s002130000500 · Cited by 195 · cited 2×
“For example, human drug discrimination studies report that the subjective effects of butorphanol are more kappa-like than mu-like (Preston et al. 1989; Preston and Bigelow 1994; see Dykstra et al. 1997 for review) and a direct dosing study suggests that butorphanol can be readily differentiated from a pure mu agonist…”
BackgroundSelectivity of Ligands for Opioid Receptors
Corbett, A. D., Paterson, S. J., & Kosterlitz, H. W. (1993) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-77460-7_26 · Cited by 184 · cited 1×
“Enadoline is a potent compound which binds with high affinity to kappa sites (Ki=0.11 nM) and is estimated to be 900- and 9000-fold more selective for kappa over mu and delta opiate receptors, respectively (Clark et al. 1988; Boyle et al. 1990; Corbett et al. 1993 ).”
BackgroundInfluentialDykstra, L. A., Gmerek, D. E., Winger, G., & Woods, J. H. (1987) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39097-x · Cited by 168
Cited by
Structure of the human κ-opioid receptor in complex with JDTic
Wu, H., Wacker, D., Mileni, M., Katritch, V., Han, G. W., Vardy, E., Liu, W., Thompson, A. A., Huang, X.-P., Carroll, F. I., et al. (2012) · Nature · doi:10.1038/nature10939 · Cited by 879
Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist
Roth, B. L., Baner, K., Westkaemper, R., Siebert, D., Rice, K. C., Steinberg, S., Ernsberger, P., & Rothman, R. B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182234399 · Cited by 784
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845 · Cited by 748
Kozlowska, K., Walker, P., McLean, L., & Carrive, P. (2015) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000065 · Cited by 468
“Lanius (2014)(110) hypothesizes that symptoms of derealization and depersonalization during tonic immobility and other dissociative states may be mediated by kappa opioids—also known as dynorphins— because their activation has been documented in experiments of tonic immobility in animals and because they are known to…”
BackgroundCarlezon, W. A., Béguin, C., DiNieri, J. A., Baumann, M. H., Richards, M. R., Todtenkopf, M. S., Rothman, R. B., Ma, Z., Lee, D. Y.-W., & Cohen, B. M. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092304 · Cited by 390
Metadata
- Authors
- Walsh, S., Strain, E., Abreu, M., & Bigelow, G.
- Affiliations
- Johns Hopkins University (US)
- AstraZeneca (United States) (US)
- Venue
- Psychopharmacology
- Published
- 2001-09-01
- Volume
- 157
- Issue
- 2
- Pages
- 151-162
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2148208755
- Cited by
- 258
- References
- 51
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 6 · 2023: 5 · 2022: 6 · 2021: 19 · 2020: 9 · 2019: 5 · 2018: 6 · 2017: 7 · 2016: 15 · 2015: 14 · 2014: 6 · 2013: 15 · 2012: 10
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service
- National Institute on Drug Abuse (K05DA000050, K05 DA00050, T32-DA07209, R01 DA10753, R01DA010753, T32DA007209)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- kappa opioid receptor agonists, butorphanol, hydromorphone, opioid pharmacodynamics, sedation, psychotomimetic effects, respiratory depression, polysubstance abuse, opioid analgesics, drug safety
- MeSH terms
- Adult, Analgesics, Opioid, Analysis of Variance, Benzofurans, Butorphanol, Hydromorphone, Dose-Response Relationship, Drug, Double-Blind Method, Female, Heroin Dependence, Humans, Male, Middle Aged, Pilot Projects, Pyrrolidines, Receptors, Opioid, kappa, Cross-Over Studies, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. https://app.cochat.ai/papers/10.1007/s002130100788
- The paper
- Walsh, S., Strain, E., Abreu, M., & Bigelow, G. (2001). Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology. https://doi.org/10.1007/s002130100788
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.